Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 320

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Evaluation of cell-free DNA approaches for multi-cancer early detection

Open access
Jamshidi, Arash, Liu, Minetta C., Klein, Eric A., Venn, Oliver, Hubbell, Earl, Beausang, John F., Gross, Samuel, Melton, Collin, Fields, Alexander P., Liu, Qinwen, Zhang, Nan, Fung, Eric T., Kurtzman, Kathryn N., Amini, Hamed, Betts, Craig, Civello, Daniel, Freese, Peter, Calef, Robert, Davydov, Konstantin, Fayzullina, Saniya, Hou, Chenlu, Jiang, Roger, Jung, Byoungsok, Tang, Susan, Demas, Vasiliki, Newman, Joshua, Sakarya, Onur, Scott, Eric, Shenoy, Archana, Shojaee, Seyedmehdi, Steffen, Kristan K., Nicula, Virgil, Chien, Tom C., Bagaria, Siddhartha, Hunkapiller, Nathan, Desai, Mohini, Dong, Zhao, Richards, Donald A., Yeatman, Timothy J., Cohn, Allen L., Thiel, David D., Berry, Donald A., Tummala, Mohan K., McIntyre, Kristi, Sekeres, Mikkael A., Bryce, Alan, Aravanis, Alexander M., Seiden, Michael V., Swanton, Charles·2022·Cancer Cell

Abstract

In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF), enabling performance comparisons. Among 10 machine-learning classifiers trained on the same samples and independently validated, when evaluated at 98% specificity, those using whole-genome (WG) methylation, single nucleotide variants with paired white blood cell background removal, and combined scores from classifiers evaluated in this study show the highest cancer signal detection sensitivities. Compared with clinical stage and tumor type, cTAF is a more significant predictor of classifier performance and may more closely reflect tumor biology. Clinical LODs mirror relative sensitivities for all approaches. The WG methylation feature best predicts cancer signal origin. WG methylation is the most promising technology for MCED and informs development of a targeted methylation MCED test.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2022.10.022

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 320

Metadata

Authors
Jamshidi, A., Liu, M. C., Klein, E. A., Venn, O., Hubbell, E., Beausang, J. F., Gross, S., Melton, C., Fields, A. P., Liu, Q., Zhang, N., Fung, E. T., Kurtzman, K. N., Amini, H., Betts, C., Civello, D., Freese, P., Calef, R., Davydov, K., Fayzullina, S., Hou, C., Jiang, R., Jung, B., Tang, S., Demas, V., Newman, J., Sakarya, O., Scott, E., Shenoy, A., Shojaee, S., Steffen, K. K., Nicula, V., Chien, T. C., Bagaria, S., Hunkapiller, N., Desai, M., Dong, Z., Richards, D. A., Yeatman, T. J., Cohn, A. L., Thiel, D. D., Berry, D. A., Tummala, M. K., McIntyre, K., Sekeres, M. A., Bryce, A., Aravanis, A. M., Seiden, M. V., & Swanton, C.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-12
Volume
40
Issue
12
Pages
1537-1549.e12
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4309413267
Cited by
320
References
47
FWCI
21.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of cell-free DNA approaches for multi-cancer early detection. https://app.cochat.ai/papers/10.1016/j.ccell.2022.10.022
The paper
Jamshidi, A., Liu, M. C., Klein, E. A., Venn, O., Hubbell, E., Beausang, J. F., Gross, S., Melton, C., Fields, A. P., Liu, Q., Zhang, N., Fung, E. T., Kurtzman, K. N., Amini, H., Betts, C., Civello, D., Freese, P., Calef, R., Davydov, K., . . . Swanton, C. (2022). Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. https://doi.org/10.1016/j.ccell.2022.10.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.